Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06422923 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
A Phase 1 study of Epilepsy, Temporal Lobe, sponsored by Neurona Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 17
- Study locations
NCT06422923: Recruiting Phase 1 study of Epilepsy, Temporal Lobe, sponsored by Neurona Therapeutics.
NCT06422923 is a Phase 1 study of Epilepsy, Temporal Lobe that is actively recruiting participants, run by Neurona Therapeutics. The registered enrollment target is 10 participants, below the 410-participant average among 4 other Epilepsy, Temporal Lobe trials with a reported enrollment target (98% lower). The trial reports 17 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06422923, a Phase 1 study of Epilepsy, Temporal Lobe, is actively recruiting participants, sponsored by Neurona Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes of subjects with drug-resistant bilateral mesial temporal lobe epilepsy.
Conditions Studied
Interventions
- BIOLOGICAL NRTX-1001
Study Locations (17)
California
- University of Southern California Keck Hospital - Los Angeles
- UC Irvine Medical Center - Orange
- Stanford University - Palo Alto
- University of California San Diego - San Diego
- University of California San Francisco - San Francisco
North Carolina
- Atrium Health - Charlotte
- Duke University Hospital - Durham
- Wake Forest Baptist Medical Center - Winston-Salem
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Illinois
- University of Chicago - Chicago
Iowa
- University of Iowa Health Care - Iowa City
New York
- SUNY Upstate Medical University - Syracuse
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-11-14 |
| Est. Completion | 2042-06-15 |
| Phase | Phase 1 |
What NCT06422923 shows while recruiting
NCT06422923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 410-participant average among 4 other Epilepsy, Temporal Lobe trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Epilepsy, Temporal Lobe appearing as the primary indexed condition, and to 1 intervention - of which NRTX-1001 is the first listed.
NCT06422923 lists 17 locations in 11 states (California, North Carolina, Arkansas).
Frequently Asked Questions
What is clinical trial NCT06422923 about?
NCT06422923 is a clinical study titled "A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)". This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes of subjects with drug-resistant bilateral mesial temporal lobe epilepsy.
What is the current status of trial NCT06422923?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-11-14. Estimated completion is 2042-06-15.
What conditions does trial NCT06422923 study?
This clinical trial studies the following conditions: Epilepsy, Temporal Lobe.
What interventions are being tested in trial NCT06422923?
The interventions under investigation include: NRTX-1001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06422923?
This trial is sponsored by Neurona Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06422923 being conducted?
This trial has 17 study locations across Arkansas, California, Colorado, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy, Temporal Lobe
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI